R. Elliott

发表

Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress

A. Ashworth, D. Cunningham, C. Lord, 2013, British Journal of Cancer.

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cells

V. Roulstone, J. Kyula, R. Vile, 2022, bioRxiv.

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

Elizabeth Iorns, Alan Ashworth, A. Ashworth, 2008, The EMBO journal.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

M. Dowsett, J. Baselga, V. Serra, 2016, Cancer research.

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

A. Ashworth, A. Tutt, T. Crook, 2008, Cancer cell.

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

A. Ashworth, B. Wang, C. Lord, 2013, Clinical Cancer Research.

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer

A. Ashworth, J. Reis-Filho, D. Cunningham, 2017, Gut.

A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D

A. Ashworth, P. Workman, C. Lord, 2008, Oncogene.

Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma*

A. Ashworth, M. Blades, C. Lord, 2016, The Journal of Biological Chemistry.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Samuel E. Jones, A. Ashworth, S. Pettitt, 2017, Cancer research.

Inactivation of effector caspases through nondegradative polyubiquitylation.

Kristoffer T G Rigbolt, Blagoy Blagoev, Marketa Zvelebil, 2008, Molecular cell.

Regulation of the Wnt signalling component PAR1A by the Peutz–Jeghers syndrome kinase LKB1

A. Ashworth, J. Spicer, Darrin P. Smith, 2003, Oncogene.

Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours

A. Ashworth, J. Reis-Filho, J. Burn, 2011, Oncogene.

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

A. Ashworth, F. André, J. Soria, 2013, Oncogene.

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors

A. Ashworth, F. Rohdich, O. Sansom, 2019, Scientific Reports.

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway

A. Ashworth, A. Bardelli, P. Seneci, 2015, Oncotarget.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

Samuel E. Jones, Amaya Garcia Munoz, A. Ashworth, 2018, Scientific Reports.

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling

A. Ashworth, C. Lord, S. Swift, 2014, Oncotarget.

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

A. Ashworth, C. Lord, N. Turner, 2015, Molecular Cancer Therapeutics.

Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors

A. Ashworth, L. Pearl, C. Springer, 2015 .

Inactivation of effector caspases through nondegradative polyubiquitylation.

M. Zvelebil, B. Blagoev, A. Bergmann, 2008, Molecular cell.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

M. Dowsett, J. Baselga, V. Serra, 2016, Cancer research.

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling

A. Ashworth, C. Lord, S. Swift, 2014, Oncotarget.

PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-κB-regulated immune response

V. Roulstone, S. Pettitt, Francesca Butera, 2023, bioRxiv.